Pancreatic Cancer Research

ResearcherUniversity of MichiganNo recent work listed

Jiayuh Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5618-8781; OpenAlex author ID A5022526482. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 8)
Trials
0
Grants
0
Labs led
2
Collaborators
21
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 13

  1. Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers15133507↗
  2. Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells. Last author DOI 10.1080/15384047.2019.1579956↗
  3. Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells. Last author DOI 10.2174/1568009618666180430123939↗
  4. L61H46 shows potent efficacy against human pancreatic cancer through inhibiting STAT3 pathway. Co-author DOI 10.2147/cmar.s159090↗
  5. Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer … First author DOI 10.21873/anticanres.12983↗
  6. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells. Last author DOI 10.3892/ijo.2018.4389↗
  7. Seed-in-Soil: Pancreatic Cancer Influenced by Tumor Microenvironment. First author DOI 10.3390/cancers9070093↗
  8. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy. Last author DOI 10.1158/1535-7163.mct-15-0921↗
  9. Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling. Co-author DOI 10.18632/oncotarget.7336↗
  10. STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells. Last author DOI 10.3892/ijo.2016.3728↗
  11. HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s. Co-author DOI 10.1158/1078-0432.ccr-13-0621↗
  12. XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. Last author DOI 10.1371/journal.pone.0046624↗
  13. LLL12 inhibits endogenous and exogenous interleukin-6-induced STAT3 phosphorylation in human pancreatic cancer cells. Last author PMID 21737619↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huey-Jen L. Lin · 3 shared papers, 2017–2023 · strength 0.53
  2. Shengling Fu · 2 shared papers, 2018 · strength 0.29
  3. Gloria Huei-Ting Su · 2 shared papers, 2019 · strength 0.28
  4. Xiang 'Anthony' Chen · 2 shared papers, 2018–2019 · strength 0.26
  5. Ling Ma · 1 shared paper, 2019 · strength 0.14
  6. Liang Xu · 2 shared papers, 2013–2016 · strength 0.08
  7. Xiaoqing Wu · 2 shared papers, 2013–2016 · strength 0.08
  8. Encheng Bai · 1 shared paper, 2018 · strength 0.08
  9. Guang Liang · 1 shared paper, 2018 · strength 0.08
  10. Chengguang Zhao · 1 shared paper, 2018 · strength 0.08
  11. Lehe Yang · 1 shared paper, 2018 · strength 0.08
  12. Xiaojuan Wu · 1 shared paper, 2016 · strength 0.08
  13. Aiguo Liu · 2 shared papers, 2011–2012 · strength 0.06
  14. Li Lin · 1 shared paper, 2016 · strength 0.06
  15. Ke Li · 1 shared paper, 2016 · strength 0.05
  16. Theodore Steven Lawrence · 1 shared paper, 2013 · strength 0.03
  17. Zhi‐Nan Chen · 1 shared paper, 2013 · strength 0.03
  18. Ling Li · 1 shared paper, 2013 · strength 0.03
  19. David M. Karnak · 1 shared paper, 2013 · strength 0.03
  20. Diane M. Simeone · 1 shared paper, 2013 · strength 0.03
  21. Yan Liu · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.